AstraZeneca PLC
23 May 2005
Dealing by Directors
Companies Act 1985 Sections 324/329
We hereby inform you that, on 23 May 2005, Sir Tom McKillop, a Director of the
Company, acquired 447 of the Company's USD0.25 Ordinary Shares at a price of
£22.64 per share following the exercise of an option under the AstraZeneca
Savings-Related Share Option Scheme.
Sir Tom McKillop's interest in the Ordinary Shares of the Company has increased
to 92,615 shares, which represents approximately 0.006 per cent of the number of
shares in issue. Sir Tom McKillop now has options over 678,611 Ordinary
Shares.
G H R Musker
Company Secretary
23 May 2005
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.